 | • レポートコード：MRC2301E011 • 出版社/出版日：Persistence Market Research / 2022年10月28日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,140,000 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,590,000 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料は、世界の黄斑変性治療市場について総合的・多面的に調査しています。本資料では、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症危機分析、需要分析・予測、治療薬別（抗血管内皮細胞増殖因子製剤、その他）分析、投与経路別（静脈内投与、硝子体内投与、その他）分析、適応疾患別（萎縮型加齢黄斑変性症、滲出型加齢黄斑変性症）分析、エンドユーザー別（病院、眼科クリニック、外来手術センター、その他）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析、構造分析、競争分析、仮定、調査方法などを整理しております。また、F. Hoffmann-La Roche Ltd.、Novartis AG、Bayer AG、Pfizer Inc.、Bausch Health Companies Inc.、Regeneron Pharmaceuticals Inc.、Amgen Incなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症危機分析 ・需要分析・予測 ・世界の黄斑変性治療市場規模：治療薬別 - 抗血管内皮細胞増殖因子製剤における市場規模 - その他における市場規模 ・世界の黄斑変性治療市場規模：投与経路別 - 静脈内投与における市場規模 - 硝子体内投与における市場規模 - その他における市場規模 ・世界の黄斑変性治療市場規模：適応疾患別 - 萎縮型加齢黄斑変性症治療の市場規模 - 滲出型加齢黄斑変性症治療の市場規模 ・世界の黄斑変性治療市場規模：エンドユーザー別 - 病院における市場規模 - 眼科クリニックにおける市場規模 - 外来手術センターにおける市場規模 - その他における市場規模 ・世界の黄斑変性治療市場規模：地域別 - 北米の黄斑変性治療市場規模 - 中南米の黄斑変性治療市場規模 - ヨーロッパの黄斑変性治療市場規模 - 東アジアの黄斑変性治療市場規模 - 南アジアの黄斑変性治療市場規模 - オセアニアの黄斑変性治療市場規模 - 中東・アフリカの黄斑変性治療市場規模 ・構造分析 ・競争分析 ・仮定 ・調査方法 |
Macular Degeneration Treatment Market: Scope of Report
The latest publication by Persistence Market Research on the global macular degeneration treatment market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers in knowing the demand for macular degeneration treatment products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the macular degeneration treatment market. Shareholders in the macular degeneration treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts can leverage insights and information presented in this Persistence Market Research study.
Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the macular degeneration treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the macular degeneration treatment market offers information divided into five important segments – drug, indication, route of administration, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug
Anti-vascular Endothelial Growth Factors
Other
Route of Administration
Intravenous Route
Intravitreal Route
Others
Indication
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
End User
Hospitals
Ophthalmology Clinics
Ambulatory Surgical Centers
Others
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for macular degeneration treatment over the coming years?
How will changing trends influence the market?
How has the COVID-19 crisis influenced market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will affect the market?
How can companies in the macular degeneration treatment market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the macular degeneration treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the macular degeneration treatment market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development and Innovation Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Recent Product Launches and Approvals
4.3. Strategic Promotional Strategies
4.4. Disease Epidemiology
4.5. Regulatory and Reimbursement Scenario
4.6. Product Pipeline Assessment
4.7. Porters Analysis
4.8. PESTLE Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Alternative Treatment Market Growth
5.2.2. Technological Advances
5.2.3. Development of Novel Products
5.2.4. Regulatory Imposition
5.2.5. Product Pipeline
5.2.6. Per Patient Spending
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Route of Administration
6.1.3. Revenue By Indication
6.1.4. Revenue By End User
6.1.5. Revenue By Country
6.2. 2021 Market Scenario
7. Global Macular Degeneration Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2012–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2022–2032
8.3.1. Anti-vascular Endothelial Growth Factor
8.3.2. Other
8.4. Market Attractiveness Analysis By Drug
9. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022–2032
9.3.1. Intravenous Route
9.3.2. Intravitreal Route
9.3.3. Others
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2012–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032
10.3.1. Dry Age-related Macular Degeneration
10.3.2. Wet Age-related Macular Degeneration
10.4. Market Attractiveness Analysis By Indication
11. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2012–2021
11.3. Current and Future Market Size (US$ Mn) and Forecast By End User, 2022–2032
11.3.1. Hospitals
11.3.2. Ophthalmology Clinics
11.3.3. Ambulatory Surgical Centers
11.3.4. Others
11.4. Market Attractiveness Analysis By End User
12. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. The Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
13.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug
13.3.3. By Route of Administration
13.3.4. By Indication
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Route of Administration
13.4.4. By Indication
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Macular Degeneration Treatment Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug
13.8.1.2.2. By Route of Administration
13.8.1.2.3. By Indication
13.8.1.2.4. By End User
13.8.2. Canada Macular Degeneration Treatment Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug
13.8.2.2.2. By Route of Administration
13.8.2.2.3. By Indication
13.8.2.2.4. By End User
14. Latin America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
14.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug
14.3.3. By Route of Administration
14.3.4. By Indication
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Route of Administration
14.4.4. By Indication
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Macular Degeneration Treatment Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Route of Administration
14.8.1.2.3. By Indication
14.8.1.2.4. By End User
14.8.2. Mexico Macular Degeneration Treatment Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Route of Administration
14.8.2.2.3. By Indication
14.8.2.2.4. By End User
14.8.3. Argentina Macular Degeneration Treatment Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Route of Administration
14.8.3.2.3. By Indication
14.8.3.2.4. By End User
15. Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
15.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug
15.3.3. By Route of Administration
15.3.4. By Indication
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Route of Administration
15.4.4. By Indication
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Macular Degeneration Treatment Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Route of Administration
15.8.1.2.3. By Indication
15.8.1.2.4. By End User
15.8.2. Italy Macular Degeneration Treatment Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Route of Administration
15.8.2.2.3. By Indication
15.8.2.2.4. By End User
15.8.3. France Macular Degeneration Treatment Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Route of Administration
15.8.3.2.3. By Indication
15.8.3.2.4. By End User
15.8.4. U.K. Macular Degeneration Treatment Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug
15.8.4.2.2. By Route of Administration
15.8.4.2.3. By Indication
15.8.4.2.4. By End User
15.8.5. Spain Macular Degeneration Treatment Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug
15.8.5.2.2. By Route of Administration
15.8.5.2.3. By Indication
15.8.5.2.4. By End User
15.8.6. BENELUX Macular Degeneration Treatment Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug
15.8.6.2.2. By Route of Administration
15.8.6.2.3. By Indication
15.8.6.2.4. By End User
15.8.7. Russia Macular Degeneration Treatment Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug
15.8.7.2.2. By Route of Administration
15.8.7.2.3. By Indication
15.8.7.2.4. By End User
16. South Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
16.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Drug
16.3.3. By Route of Administration
16.3.4. By Indication
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Route of Administration
16.4.4. By Indication
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Macular Degeneration Treatment Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Route of Administration
16.8.1.2.3. By Indication
16.8.1.2.4. By End User
16.8.2. Indonesia Macular Degeneration Treatment Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Route of Administration
16.8.2.2.3. By Indication
16.8.2.2.4. By End User
16.8.3. Malaysia Macular Degeneration Treatment Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Route of Administration
16.8.3.2.3. By Indication
16.8.3.2.4. By End User
16.8.4. Thailand Macular Degeneration Treatment Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug
16.8.4.2.2. By Route of Administration
16.8.4.2.3. By Indication
16.8.4.2.4. By End User
17. East Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
17.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Drug
17.3.3. By Route of Administration
17.3.4. By Indication
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Route of Administration
17.4.4. By Indication
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints – Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Macular Degeneration Treatment Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug
17.8.1.2.2. By Route of Administration
17.8.1.2.3. By Indication
17.8.1.2.4. By End User
17.8.2. Japan Macular Degeneration Treatment Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug
17.8.2.2.2. By Route of Administration
17.8.2.2.3. By Indication
17.8.2.2.4. By End User
17.8.3. South Korea Macular Degeneration Treatment Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug
17.8.3.2.2. By Route of Administration
17.8.3.2.3. By Indication
17.8.3.2.4. By End User
18. Oceania Macular Degeneration Treatment Market 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
18.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug
18.3.3. By Route of Administration
18.3.4. By Indication
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Route of Administration
18.4.4. By Indication
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints – Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Macular Degeneration Treatment Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Route of Administration
18.8.1.2.3. By Indication
18.8.1.2.4. By End User
18.8.2. New Zealand Macular Degeneration Treatment Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Route of Administration
18.8.2.2.3. By Indication
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
19.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
19.3.1. By Country
19.3.1.1. Turkey
19.3.1.2. GCC Countries
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug
19.3.3. By Route of Administration
19.3.4. By Indication
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug
19.4.3. By Route of Administration
19.4.4. By Indication
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants – Intensity Mapping
19.7. Drivers and Restraints – Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. Turkey Macular Degeneration Treatment Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug
19.8.1.2.2. By Route of Administration
19.8.1.2.3. By Indication
19.8.1.2.4. By End User
19.8.2. GCC Countries Macular Degeneration Treatment Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug
19.8.2.2.2. By Route of Administration
19.8.2.2.3. By Indication
19.8.2.2.4. By End User
19.8.3. South Africa Macular Degeneration Treatment Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug
19.8.3.2.2. By Route of Administration
19.8.3.2.3. By Indication
19.8.3.2.4. By End User
19.8.4. North Africa Macular Degeneration Treatment Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug
19.8.4.2.2. By Route of Administration
19.8.4.2.3. By Indication
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis (%) of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Product footprint by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive (Tentative List)
21.3.1. F. Hoffmann-La Roche Ltd.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Key Financials
21.3.1.4. Sales Footprint
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.2. Novartis AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Key Financials
21.3.2.4. Sales Footprint
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.3. Bayer AG
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Key Financials
21.3.3.4. Sales Footprint
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.4. Pfizer Inc.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Key Financials
21.3.4.4. Sales Footprint
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.5. Bausch Health Companies Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Key Financials
21.3.5.4. Sales Footprint
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.6. Regeneron Pharmaceuticals Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Key Financials
21.3.6.4. Sales Footprint
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.7. Amgen Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Key Financials
21.3.7.4. Sales Footprint
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.8. Biogen
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Key Financials
21.3.8.4. Sales Footprint
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.9. Samsung Bioepis
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Key Financials
21.3.9.4. Sales Footprint
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.10. Santen Pharmaceutical Co., Ltd.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Key Financials
21.3.10.4. Sales Footprint
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology